Related Experiment Videos
Adeno-associated virus-mediated gene transfer to the neonatal brain
1Department of Pathology, Gene Therapy Center, University of Alabama-Birmingham, BMR2, Room 430, 901 19th Street South, Birmingham, AL 35294-2172, USA.
Insights
Gene therapy using adeno-associated virus (AAV) vectors can treat neonatal central nervous system (CNS) diseases. This study details a precise method for AAV delivery to the neonatal brain, enabling early intervention and developmental research.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Metabolic diseases require early intervention to prevent irreversible developmental damage, especially in the central nervous system (CNS).
- Gene transfer to the neonatal brain offers potential therapeutic strategies for early-onset CNS disorders.
- Adeno-associated virus (AAV) vectors show promise for neonatal CNS gene transduction, with preclinical studies demonstrating persistent expression into adulthood.
Purpose of the Study:
- To describe a method for direct, intraparenchymal injection of AAV into the neonatal brain.
- To provide a technique for evaluating the effects of in vivo gene expression on early brain development.
Main Methods:
- Detailed description of a surgical technique for direct intraparenchymal injection of AAV vectors into the neonatal brain.
- Comparison of intraparenchymal injection with other neonatal brain transduction methods (intraventricular infusion, intravenous administration).
Main Results:
- Intraparenchymal injection achieves high levels of localized gene expression in the neonatal brain.
- Intraventricular infusion results in more widespread gene distribution in neonates.
Conclusions:
- Direct intraparenchymal AAV injection is a viable method for targeted gene transfer in the neonatal brain.
- This technique facilitates research into the impact of gene therapy on early brain development and the treatment of neonatal CNS diseases.
Abstract:
For many metabolic diseases, early treatment is necessary to prevent irreversible developmental damage. This is particularly true for childhood diseases that affect the central nervous system (CNS). The development of effective techniques for gene transfer to the neonatal brain would provide a new set of therapeutic options for many of these disorders. Vectors based on adeno-associated virus (AAV) have shown promise as agents for neonatal CNS transduction. In preclinical animal models, a single treatment with AAV vectors at birth has been shown to produce persistent CNS expression of transduced genes into adulthood. Transduction of the neonatal brain has been accomplished by a variety of methods, including direct intraparenchymal injection, intraventricular infusion, and intravenous administration. Of these methods, intraparenchymal injection provides the highest levels of localized activity, while intraventricular infusion results in a more widespread distribution of activity when performed in the neonate. Here we describe a method for direct, intraparenchymal injection of AAV into the neonatal brain. This technique provides a method for investigators to evaluate the effects of in vivo expression of exogenous genes on the process of early brain development.